Mohamadreza Savaee - Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
Ali Bakhshi - Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
Fatemeh Yaghoubi - Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
Fatemeh Pourrajab - Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Koorosh Goodarzvand Chegini - Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.

Background: Prostate cancer is known as one of the most prevalent health disorders in the male population globally. The aim of the current study was to evaluate the effects of separate and concomitant use of MK-۲۲۰۶ and salinomycin on prostate cancer cell line.  Methods: The antitumor potential of separate and concomitant use of MK-۲۲۰۶ and salinomycin was evaluated in a panel of prostate cancer cell line (PC-۳). To get insights into the underlying mechanism of action, different assays including the rate of apoptosis, cell viability, and gene expression were performed in treated prostate cancer cells. Results: A significant reduction was detected in the viability percentage of prostate cancer cells (p< ۰.۰۰۱) and the rate of Akt expression (p< ۰.۰۰۱) in all salinomycin, MK-۲۲۰۶, and salinomycin+MK-۲۲۰۶ groups compared to the negative control group. Furthermore, in comparison with the negative control group, there was a notable increase in both the rate of Bad expression (p< ۰.۰۰۱) and prostate cancer cells apoptosis after salinomycin, MK-۲۲۰۶, and salinomycin+MK-۲۲۰۶ treatments. Moreover, the concomitant use of salinomycin+MK-۲۲۰۶ revealed synergistic improvements regarding the viability of prostate cancer cells and the rate of the Akt and Bad expressions compared to the separate administration of salinomycin and MK-۲۲۰۶ (all p< ۰.۰۵). Conclusions: The findings of the present study may contribute to improving the efficacy of the therapies regarding the management of prostate cancer and providing a beneficial strategy in clinical trials.

Apoptosis, Gene Expression, MK ۲۲۰۶, Prostatic Neoplasms, Salinomycin.